OnKure Therapeutics (OKUR) Cash from Operations (2020 - 2026)
OnKure Therapeutics' (OKUR) quarterly Cash from Operations came in at 12938000.0 in Q1 2026, up 7.62% YoY from 12022073.38 in Q1 2025, and down 12.39% on a QoQ basis from 11512000.0 in Q4 2025.
OnKure Therapeutics (OKUR) Cash from Operations (2020 - 2026) Analysis & Trends
OnKure Therapeutics (OKUR) has 7 years of Cash from Operations data on file, last reported at 12938000.0 in Q1 2026.
- Quarterly Cash from Operations rose 7.62% year-over-year to 12938000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 50761000.0 (up 6.85% YoY) and the FY2025 annual result came in at 51828000.0, down 1.39% from the prior year.
- Cash from Operations slipped to 12938000.0 in Q1 2026, from 11512000.0 in the prior quarter.
- In the past five years, Cash from Operations ranged from a high of 9383000.0 in Q4 2023 to a low of 23354000.0 in Q4 2024.
- A 5-year average of 11634764.71 and a median of 11956000.0 in 2022 frame the typical range for Cash from Operations.
- Annual changes were most pronounced in 2023 — Cash from Operations surged 160.1% — and 2024, when it tumbled 348.9%.
- Tracing OKUR's Cash from Operations over 5 years: stood at 15613000.0 in 2022, then surged by 160.1% to 9383000.0 in 2023, then sank by 348.9% to 23354000.0 in 2024, then surged by 50.71% to 11512000.0 in 2025, then retreated by 12.39% to 12938000.0 in 2026.
- The last three Cash from Operations figures came in at 12938000.0 (Q1 2026), 11512000.0 (Q4 2025), and 13037000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 326.72 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 360.27 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -88.83 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 728.46 Mn |
| 10 | OnKure Therapeutics | 195.74 Mn | 19.35 Mn | - | -10.35 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -10.35 Mn |
| Jun 30, 2026 | -10.35 Mn |
| Mar 31, 2026 | -12.94 Mn |
| Mar 31, 2026 | -12.94 Mn |
| Dec 31, 2025 | -11.51 Mn |
| Dec 31, 2025 | -11.51 Mn |
| Sep 30, 2025 | -13.04 Mn |
| Sep 30, 2025 | -13.04 Mn |
| Jun 30, 2025 | -13.27 Mn |
| Jun 30, 2025 | -13.27 Mn |
| Mar 31, 2025 | -14.01 Mn |
| Mar 31, 2025 | -14.01 Mn |
| Dec 31, 2024 | -23.35 Mn |
| Dec 31, 2024 | -23.35 Mn |
| Sep 30, 2024 | -10.66 Mn |
| Sep 30, 2024 | -10.66 Mn |
| Jun 30, 2024 | -6.47 Mn |
| Jun 30, 2024 | -6.47 Mn |
| Mar 31, 2024 | -10.63 Mn |
| Mar 31, 2024 | -10.63 Mn |